281 related articles for article (PubMed ID: 23287624)
1. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Löwenberg B
Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
[TBL] [Abstract][Full Text] [Related]
2. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
[No Abstract] [Full Text] [Related]
3. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
4. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
[No Abstract] [Full Text] [Related]
5. Is cytarabine required in the treatment of acute promyelocytic leukemia?
Adès L; Fenaux P
Curr Hematol Malig Rep; 2006 Jun; 1(2):122-5. PubMed ID: 20425342
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
[TBL] [Abstract][Full Text] [Related]
8. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
[No Abstract] [Full Text] [Related]
9. High-dose cytarabine induction for acute myeloid leukemia.
Shepherd JD; Barnett MJ; Philips GL
Blood; 1996 Jul; 88(2):754-5. PubMed ID: 8695826
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.
Wu D; Duan C; Chen L; Chen S
Sci Rep; 2017 Aug; 7(1):9509. PubMed ID: 28842676
[TBL] [Abstract][Full Text] [Related]
11. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
Kolla BC; Halim NAA; Cao Q; Sachs Z; Warlick E; Weisdorf D; Ho AYL; Chuan WG; Lao Z; He F
Br J Haematol; 2021 Jul; 194(1):140-144. PubMed ID: 33843048
[TBL] [Abstract][Full Text] [Related]
12. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
13. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.
Kimura S; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Yamasaki R; Ashizawa M; Machishima T; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
Hematology; 2014 Mar; 19(2):107-12. PubMed ID: 23683842
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine-based consolidation therapy in AML.
Brower V
Lancet Oncol; 2017 Apr; 18(4):e201. PubMed ID: 28262461
[No Abstract] [Full Text] [Related]
15. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Deisseroth A; Farrell A; Justice R; Kane R; Sridhara R; Chen H; He K; Pazdur R
Blood; 2010 Jan; 115(2):430. PubMed ID: 20075171
[No Abstract] [Full Text] [Related]
19. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
Ochs MA; Perissinotti AJ; Marini BL; Burke PW; Bixby DL; Pettit KM; Benitez LL
Leuk Res; 2021 Mar; 102():106517. PubMed ID: 33561633
[TBL] [Abstract][Full Text] [Related]
20. Cytarabine dose for acute myeloid leukemia.
Mori J; Tsubokura M; Kami M
N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
